Noema Pharma is focused on developing innovative therapies for central nervous system (CNS) conditions, particularly those that are often overlooked or classified as orphan diseases. Their pipeline includes several mid-clinical-stage therapeutics aimed at addressing a range of CNS-mediated disorders, such as persistent seizures associated with Tuberous Sclerosis Complex, severe pain from Trigeminal Neuralgia, involuntary tics related to Tourette Syndrome, and symptoms of menopause. The company employs a variety of mechanisms to target these conditions, including negative allosteric modulation of specific glutamate receptors and phosphodiesterase inhibition, which are designed to restore balance in neuronal signaling and alleviate debilitating symptoms.

The lead compounds in Noema's pipeline include Basimglurant (NOE-101), a negative allosteric modulator of mGlu5 receptors, which is being investigated for its efficacy in managing seizures and pain. Additionally, Gemlapodect (NOE-105), a selective PDE10A inhibitor, is being explored for its potential to modulate dopamine receptor signaling in Tourette Syndrome and Childhood Onset Fluency Disorder. Another candidate, NOE-115, is a monoamine modulator aimed at treating vasomotor symptoms associated with menopause. Each of these therapeutics has shown promise in preclinical and early clinical studies, demonstrating safety and tolerability, and they represent Noema Pharma's commitment to transforming the treatment landscape for CNS disorders.

Switzerland

Noema Pharma is a clinical-stage biotech company targeting debilitating central nervous system (CNS) indications. They are committed to developing treatments for debilitating disorders of the central nervous system.

Noema Pharma

Company Details